Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
STOK Stock Chart & Stats
$35.05
-$0.34(-3.65%)
At close: 4:00 PM EST
$35.05
-$0.34(-3.65%)
Day’s Range― - ―
52-Week Range$6.89 - $40.22
Previous CloseN/A
Volume337.58K
Average Volume (3M)863.37K
Market Cap
$2.03B
Enterprise Value$1.99B
Total Cash (Recent Filing)$284.67M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 11, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding59,150,790
10 Day Avg. Volume588,738
30 Day Avg. Volume863,370
Financial Highlights & Ratios
PEG Ratio2.94
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue10.79
Enterprise Value/Gross Profit10.91
Enterprise Value/Ebitda-140.53
Forecast
1Y Price Target
$46.71Price Target Upside33.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.38
Revenue Forecast (FY)$26.96M
Bulls Say, Bears Say
Bulls Say
Pricing And Valuation UpsideAnalyst raised the assumed net price to better reflect pricing for severe rare‑disease therapies, a change that materially increases the company's valuation and supports a higher price target.
Regulatory Pathway And Filing StrategyRegulators signaled that a reduction in seizure frequency could support approval and a planned rolling application could enable submission of interim seizure data while longer‑term syndrome measures mature, potentially accelerating regulatory review.
Therapeutic DifferentiationAnalyst highlights zorevunersen's potential to modify disease course in Dravet syndrome, which could substantially increase long‑term clinical value and demand beyond seizure control.
Bears Say
Data Robustness And Regulatory ScrutinyOpen‑label trial designs and regulators' view of key analyses as post hoc have led to requests for additional Vineland‑3 analysis, increasing uncertainty around approval timing and potential volatility.
International Pricing And Revenue UnpredictabilityInternational pricing rules and potential most‑favored‑nation arrangements could create unpredictability for ex‑US royalties and revenue, complicating revenue forecasts and commercial outlook.
Labeling Strategy RiskPursuit of a broader syndrome‑level label that includes cognitive and behavioral measures may lengthen the approval process and delay market access compared with a narrower seizure‑focused approach.
Stoke Therapeutics News
STOK FAQ
What was Stoke Therapeutics Inc’s price range in the past 12 months?
Stoke Therapeutics Inc lowest stock price was $6.89 and its highest was $40.22 in the past 12 months.
What is Stoke Therapeutics Inc’s market cap?
Stoke Therapeutics Inc’s market cap is $2.03B.
When is Stoke Therapeutics Inc’s upcoming earnings report date?
Stoke Therapeutics Inc’s upcoming earnings report date is May 11, 2026 which is in 27 days.
How were Stoke Therapeutics Inc’s earnings last quarter?
Stoke Therapeutics Inc released its earnings results on Mar 11, 2026. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.744 by -$0.216.
Is Stoke Therapeutics Inc overvalued?
According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued.
Does Stoke Therapeutics Inc pay dividends?
Stoke Therapeutics Inc does not currently pay dividends.
What is Stoke Therapeutics Inc’s EPS estimate?
Stoke Therapeutics Inc’s EPS estimate is -0.81.
How many shares outstanding does Stoke Therapeutics Inc have?
Stoke Therapeutics Inc has 59,150,790 shares outstanding.
What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?
Stoke Therapeutics Inc reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.744. Following the earnings report the stock price went down -1.069%.
Which hedge fund is a major shareholder of Stoke Therapeutics Inc?
Currently, no hedge funds are holding shares in STOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.71 (33.27% Upside)
$46.71 (33.27% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 528.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $552.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
426.53%
12-Months-Change
Fundamentals
Return on Equity
-2.05%
Trailing 12-Months
Asset Growth
54.09%
Trailing 12-Months
Company Description
Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
STOK Stock 12 Month Forecast
Average Price Target
$46.71
▲(33.27% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Xeris Pharmaceuticals
―
―
Rapport Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---